Fujirebio completes Innogenetics acquisition
This article was originally published in The Gray Sheet
Executive Summary
Japanese diagnostics firm Fujirebio closes $112 million purchase of Belgian specialty diagnostics firm Innogenetics from Abbott Sept. 24. Abbott acquired Innogenetics in February as part of its $6.2 billion acquisition of Solvay Pharmaceuticals, but the divestiture was required to gain European Commission approval of the Solvay transaction. The Fujirebio pact was first announced in July. Both Fujirebio and Innogenetics develop diagnostics in areas such as infectious disease, genetic testing, transplantation and neuro-degeneration. Innogenetics also develops oncology tests, and has a special focus on molecular diagnostics and multiparameter testing
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.